147 related articles for article (PubMed ID: 21689773)
1. Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study.
Gilman AL; Schultz KR; Goldman FD; Sale GE; Krailo MD; Chen Z; Langholz B; Jacobsohn DA; Chan KW; Ryan RE; Kellick M; Neudorf SM; Godder K; Sandler ES; Sahdev I; Grupp SA; Sanders JE; Wall DA
Biol Blood Marrow Transplant; 2012 Jan; 18(1):84-91. PubMed ID: 21689773
[TBL] [Abstract][Full Text] [Related]
2. Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031.
Rozmus J; Schultz KR; Wynne K; Kariminia A; Satyanarayana P; Krailo M; Grupp SA; Gilman AL; Goldman FD
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1804-13. PubMed ID: 21669298
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031.
Cuvelier GD; Kariminia A; Fujii H; Aslanian S; Wall D; Goldman F; Grupp SA; Dunn SE; Krailo M; Shapiro LH; Gilman A; Schultz KR
Bone Marrow Transplant; 2010 Nov; 45(11):1653-7. PubMed ID: 20190833
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.
Fujii H; Cuvelier G; She K; Aslanian S; Shimizu H; Kariminia A; Krailo M; Chen Z; McMaster R; Bergman A; Goldman F; Grupp SA; Wall DA; Gilman AL; Schultz KR
Blood; 2008 Mar; 111(6):3276-85. PubMed ID: 17925486
[TBL] [Abstract][Full Text] [Related]
5. An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease.
Treister N; Li S; Kim H; Lerman M; Sultan A; Alyea EP; Armand P; Cutler C; Ho V; Koreth J; Antin JH; Soiffer R
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2084-2091. PubMed ID: 27590106
[TBL] [Abstract][Full Text] [Related]
6. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.
Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D
Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907
[TBL] [Abstract][Full Text] [Related]
7. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
[TBL] [Abstract][Full Text] [Related]
10. A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Fong T; Trinkaus K; Adkins D; Vij R; Devine SM; Tomasson M; Goodnough LT; Lopez S; Graubert T; Shenoy S; Dipersio JF; Khoury HJ
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1201-6. PubMed ID: 17889357
[TBL] [Abstract][Full Text] [Related]
11. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
Soiffer RJ; Kim HT; McGuirk J; Horwitz ME; Johnston L; Patnaik MM; Rybka W; Artz A; Porter DL; Shea TC; Boyer MW; Maziarz RT; Shaughnessy PJ; Gergis U; Safah H; Reshef R; DiPersio JF; Stiff PJ; Vusirikala M; Szer J; Holter J; Levine JD; Martin PJ; Pidala JA; Lewis ID; Ho VT; Alyea EP; Ritz J; Glavin F; Westervelt P; Jagasia MH; Chen YB
J Clin Oncol; 2017 Dec; 35(36):4003-4011. PubMed ID: 29040031
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD.
Chronic GVHD Consortium
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1114-20. PubMed ID: 21664473
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience.
Teusink-Cross A; Davies SM; Grimley MS; Chandra S; Flannery A; Dandoy CE; Nelson AS; Marsh RA; Jacoby B; Lane A; Khandelwal P
Pediatr Transplant; 2020 May; 24(3):e13692. PubMed ID: 32202691
[TBL] [Abstract][Full Text] [Related]
14. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
[TBL] [Abstract][Full Text] [Related]
15. Hydrogen in Patients With Corticosteroid-Refractory/Dependent Chronic Graft-Versus-Host-Disease: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial.
Qian L; Liu M; Shen J; Cen J; Zhao D
Front Immunol; 2020; 11():598359. PubMed ID: 33324415
[TBL] [Abstract][Full Text] [Related]
16. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
[TBL] [Abstract][Full Text] [Related]
17. Verification of the new grading scale for ocular chronic graft-versus-host disease developed by the German-Austrian-Swiss consensus conference on chronic GVHD.
Blecha C; Wolff D; Holler B; Holler E; Weber D; Vogt R; Helbig H; Dietrich-Ntoukas T
Ann Hematol; 2016 Feb; 95(3):493-9. PubMed ID: 26659079
[TBL] [Abstract][Full Text] [Related]
18. CXCL9 Predicts Severity at the Onset of Chronic Graft-versus-host Disease.
Giesen N; Schwarzbich MA; Dischinger K; Becker N; Hummel M; Benner A; Radujkovic A; Müller-Tidow C; Dreger P; Luft T
Transplantation; 2020 Nov; 104(11):2354-2359. PubMed ID: 31929430
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
[TBL] [Abstract][Full Text] [Related]
20. National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution.
Lawitschka A; Gueclue ED; Januszko A; Körmöczi U; Rottal A; Fritsch G; Bauer D; Peters C; Greinix HT; Pickl WF; Kuzmina Z
Front Immunol; 2019; 10():1879. PubMed ID: 31507582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
